Table 2.
Demographic, Laboratory, and Clinical Characteristics
| Chararacteristic | Patients, No. (%)a (n = 53) |
|---|---|
| Demographics | |
| Age, median (IQR), y | 45 (30–74) |
| Male sex | 39 (74) |
| Race | |
| Asian | 2 (4) |
| Black | 1 (2) |
| Native American | 1 (2) |
| White | 43 (81) |
| Refused/unknown | 6 (11) |
| Disease status | |
| Prior lines of therapy, median (IQR) | 3 (2–7) |
| Relapse after HSCT | 19 (36) |
| Hematologic parameters before CTI | |
| ALC <300 cells/µL | 30 (57) |
| Lymphopenia duration, median (IQR), d | 3 (1–42) |
| ANC <500 cells/µL | 18 (34) |
| Neutropenia duration, median (IQR), d | 12 (3–83) |
| Hematologic parameters on day of CTI | |
| ALC <300 cells/µL | 31 (58) |
| ANC <500 cells/µL | 23 (43) |
| Antimicrobial prophylaxis before CTI | |
| Antibacterial prophylaxis | 0 (0) |
| Antifungal prophylaxis | |
| Micafungin | 32 (60) |
| Fluconazole | 1 (2) |
| Posaconazole | 3 (6) |
| Voriconazole | 6 (11) |
| None | 11 (21) |
| Anti-Pneumocystis prophylaxis | |
| Atovaquone | 2 (4) |
| Dapsone | 3 (6) |
| Pentamidine | 9 (17) |
| Trimethoprim-sulfamethoxazole | 32 (60) |
| None | 7 (13) |
| Antiviral prophylaxis | |
| Acyclovir | 38 (72) |
| Famciclovir | 1 (2) |
| Valacyclovir | 11 (21) |
| Valganciclovir | 2 (4) |
| None | 1 (2) |
| Cytokine release syndrome | |
| Grade 0 | 8 (15) |
| Grade 1–2 | 31 (59) |
| Grade 3–5 | 14 (26) |
Abbreviations: ALC, absolute lymphocyte count; ANC, absolute neutrophil count; CTI, chimeric antigen receptor T-cell infusion; HSCT, hematopoietic stem cell transplantation; IQR, interquartile range.
aData represent No. (%) of patients unless otherwise identified as median (IQR).